gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Dec 2016.

Cytochrome P450, family 2, subfamily C, polypeptide 9

This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by rifampin. The enzyme is known to metabolize many xenobiotics, including phenytoin, tolbutamide, ibuprofen and S-warfarin. Studies identifying individuals who are poor metabolizers of phenytoin and tolbutamide suggest that this gene is polymorphic. The gene is located within a cluster of cytochrome P450 genes on chromosome 10q24. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: CYP3A4, CYP2C19, Cyp, CYP2D6, CYP1A1
Papers on CYP2C9
Association of genetic polymorphisms of CYP2C9 and VKORC1 with bleeding following warfarin: A case-control study.
Thatte, Mumbai, India. In Curr Clin Pharmacol, Feb 2016
This study aimed to assess the association of CYP2C9 and VKORC1 with the development of bleeding following warfarin.
Absence of ethnic differences in the pharmacokinetics of moxifloxacin, simvastatin, and meloxicam among three East Asian populations and Caucasians.
Kawai et al., Tokyo, Japan. In Br J Clin Pharmacol, Feb 2016
Intrinsic factors (polymorphism of UGT1A1 for moxifloxacin, SLCO1B1 for simvastatin, and CYP2C9 for meloxicam) were also examined.
Cannabinoids and Cytochrome P450 Interactions.
Juřica et al., Brno, Czech Republic. In Curr Drug Metab, Jan 2016
The enzymes CYP2C9, CYP2C19, and CYP3A4 catalyze most of their hydroxylations.
Pharmacogenetics of healthy volunteers in Puerto Rico.
Duconge et al., In Drug Metabol Personal Ther, Jan 2016
In addition, polymorphisms in genes that encode for members of the CYP450 family (CYP2C9, CYP2C19, and CYP2D6) are also available due to their relevance in the metabolism of drugs.
Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.
LLerena et al., Badajoz, Spain. In Expert Opin Drug Metab Toxicol, Dec 2015
INTRODUCTION: Notably differences in CYP2C9 allele frequencies among worldwide populations have been reported, with an interesting low frequency of the CYP2C9*2 allele in Amerindians compared with Admixed and European populations.
Clinical Pharmacology of Phenobarbital in Neonates: Effects, Metabolism and Pharmacokinetics.
Pacifici, Pisa, Italy. In Curr Pediatr Rev, Dec 2015
Phenobarbital is metabolized in the liver by CYP2C9 with minor metabolism by CYP2C19 and CYP2E1.
High prevalence of VKORC1*3 (G9041A) genetic polymorphism in north Indians: A study on patients with cardiac disorders on acenocoumarol.
Varma et al., In Drug Discov Ther, Dec 2015
This was a prospective hospital based study in which allele and genotypic frequencies of CYP2C9 gene polymorphisms; 430C>T and 1075A>C and VKORC1 gene polymorphisms; 1639G>A, 9041G>A and 6009C>T in 106 alleles of north Indian patients with valve replacement on acenocoumarol were determined and their effect on acenocoumarol dosing was studied.
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Sabatine et al., Boston, United States. In Lancet, Jul 2015
A subgroup of patients was included in a prespecified genetic analysis and genotyped for variants in CYP2C9 and VKORC1.
Effect of acute paraquat poisoning on CYP450 isoforms activity in rats by cocktail method.
Ma et al., Lishui, China. In Int J Clin Exp Med, 2014
The influence of acute paraquat poisoning on the activities of CYP450 isoforms CYP2B6, CYP1A2, CYP2C9, CYP2D6, CYP3A4 and CYP2C19 were evaluated by cocktail method, they were responded by the changes of pharmacokinetic parameters of bupropion, phenacetin, tolbutamide, metoprolol, midazolam and omeprazole.
Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray.
Li et al., Changchun, China. In Int J Clin Exp Med, 2014
Among them, the most important enzymes are highly polymorphic CYP2C9, CYP2C19, CYP2D6 and CYP3A5, which are responsible for about 40% of the metabolism of clinical used drugs.
Half-Life of Sulfonylureas in HNF1A and HNF4A Human MODY Patients is not Prolonged as Suggested by the Mouse Hnf1a(-/-) Model.
Heneberg et al., Praha, Czech Republic. In Curr Pharm Des, 2014
DESIGN AND METHODS: Single doses of 3 mg glipizide and 5 mg glibenclamide/glyburide were administered sequentially to seven HNF1A/HNF4A MODY subjects and six control individuals matched for their age, BMI and CYP2C9 genotype.
Genetic variants associated with phenytoin-related severe cutaneous adverse reactions.
Japan Pharmacogenomics Data Science Consortium et al., Taipei, Taiwan. In Jama, 2014
RESULTS: The GWAS discovered a cluster of 16 single-nucleotide polymorphisms in CYP2C genes at 10q23.33 that reached genome-wide significance.
Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming.
Deng et al., Beijing, China. In Cell Stem Cell, 2014
Importantly, the metabolic activities of CYP3A4, CYP1A2, CYP2B6, CYP2C9, and CYP2C19 are comparable between hiHeps and freshly isolated primary human hepatocytes.
A randomized trial of genotype-guided dosing of acenocoumarol and phenprocoumon.
EU-PACT Group et al., Aş Şanamayn, Syria. In N Engl J Med, 2014
METHODS: We conducted two single-blind, randomized trials comparing a genotype-guided dosing algorithm that included clinical variables and genotyping for CYP2C9 and VKORC1 with a dosing algorithm that included only clinical variables, for the initiation of acenocoumarol or phenprocoumon treatment in patients with atrial fibrillation or venous thromboembolism.
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.
Johnson et al., Chicago, United States. In Lancet, 2013
BACKGROUND: VKORC1 and CYP2C9 are important contributors to warfarin dose variability, but explain less variability for individuals of African descent than for those of European or Asian descent.
Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Sun et al., Beijing, China. In J Thromb Thrombolysis, 2012
The multiple linear regression model including VKORC1-1639G>A, CYP2C9, CYP4F2 and clinical factors (body surface area (BSA) and age) could explain 42 % of the variance in the warfarin maintenance dose.
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
Tait et al., Glasgow, United Kingdom. In Br J Haematol, 2012
Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates.
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Yu et al., Nanjing, China. In Thromb Haemost, 2012
Report algorithm predicting warfarin dose in Chinese Han patients with valvular atrial fibrillation based on CYP4F2/CYP2C9/VKORC1 polymorphisms.
Rapid testing of clopidogrel resistance by genotyping of CYP2C19 and CYP2C9 polymorphisms using denaturing on-chip capillary electrophoresis.
Benesova et al., Praha, Czech Republic. In Electrophoresis, 2012
Using chipCE, we present an optimization for allele separation of CYP2C19 I331V, CYP2C9 R144C, and CYP2C9 I359L polymorphisms employing run temperatures of up to 55 degrees C.
Warfarin pharmacogenetics: polymorphisms of the CYP2C9, CYP4F2, and VKORC1 loci in a genetically admixed Omani population.
Krishnamoorthy et al., Oman. In Hum Biol, 2012
The researchers evaluated the prevalence of the CYP2C9 polymorphism in a population of Omanis.
share on facebooktweetadd +1mail to friends